0
Boehringer Ingelheim, a global leader in animal health, is proud to celebrate 25 years of partnering with veterinarians and producers to combat PRRS (Porcine Reproductive and Respiratory Syndrome) in Europe and more than 25 years in the US. In addition to offering a leading full range of PRRS modified-live vaccines including Ingelvac® PRRS MLV, Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU, the Company is in the unique position to offer a holistic approach to PRRS control through collaborative research, innovative diagnostics and services.
Martin Forchieri, Head of Vaccine Franchise, Swine Business at Boehringer Ingelheim, shared: “All too often the term ‘journey’ is used for what merely turns out to be projects – with regards to Ingelvac® PRRS MLV though, it has been and continues to be a learning journey at its best. Over the last 25 years both Boehringer Ingelheim as well as the swine industry have learned so much about how to best control and prevent PRRS. Harvesting such learnings contributes to better PRRS control as well as to more efficient swine health management overall spreading across diseases, disciplines and technologies – what a journey indeed.”
Boehringer Ingelheim PRRS franchise has been the market leader in PRRS vaccine segment for more than 10 years. The Company achieved more than 1.7 billion doses sold of PRRS Franchise in 2020 since Ingelvac® PRRS MLV was launched in 1994 in the US; the product was approved two years later in Europe. In addition, 2015 saw a launch of Ingelvac PRRSFLEX® EU and ReproCyc® PRRS EU against PRRSV type 1 infection in the EU.
As a science-driven company, Boehringer Ingelheim has sponsored the European PRRS Research Award for 16 years to support applied research for improved control of the PRRS swine disease, as well as more than 48 research projects with value of 1.2 million euro to support the innovation of PRRS control.
The Company is proud to have been continuously able to improve pig health and performance, its customers’ production and profit - today and in the future.
June 30, 2021 - Boehringer Ingelheim
